Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
Diabetes Ther
.
2020 Dec;11(12):3011-3013.
doi: 10.1007/s13300-020-00842-w.
Authors
Cristian Guja
1
,
Juan P Frías
2
,
Lisa Suchower
3
,
Elise Hardy
4
,
Galina Marr
4
,
C David Sjöström
5
,
Serge A Jabbour
6
Affiliations
1
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. cristian.guja@b.astral.ro.
2
National Research Institute, Los Angeles, CA, USA.
3
Kelly Services, Gaithersburg, MD, USA.
4
AstraZeneca, Gaithersburg, MD, USA.
5
AstraZeneca, Gothenburg, Sweden.
6
Thomas Jefferson University, Philadelphia, PA, USA.
PMID:
33011938
PMCID:
PMC7644701
DOI:
10.1007/s13300-020-00842-w
Abstract
In the original article, the Table 1 has published with error.
Publication types
Published Erratum